Deprecated: Creation of dynamic property PL_VBP_License::$version is deprecated in /var/www/healingmaps.imarkdev.com/wp-content/plugins/video-background-pro/license-page.php on line 92

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the listeo-data-scraper domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/healingmaps.imarkdev.com/wp-includes/functions.php on line 6170

Deprecated: Creation of dynamic property Vidbg_WPBakery::$vc_row_atts is deprecated in /var/www/healingmaps.imarkdev.com/wp-content/plugins/video-background-pro/inc/classes/vidbg_wpbakery.php on line 49
Psychedelic Industry News - HealingMaps

Oregon Dropped Its Psilocybin Fee Hike After Licensees Said They Would Walk

The Oregon Health Authority wanted $20,000 annual licenses. Community surveys suggested enough licensees would quit that the state would collect less than it does today.

Read More

The DEA Wants Five More Tryptamines in Schedule I. Comments Close October 23

A proposed rule would place five tryptamines into Schedule I. It is the second attempt at the same action, and comments close October 23.

Read More

An MDMA Course Takes 34 Clinician Hours Per Patient

Israeli MDMA trials run 15 sessions over three to four months, including an eight hour dosing day with two therapists present. The staffing math is the part US clinics should be reading.

Read More

6 Regulatory Deadlines Ketamine Clinics Should Have on the Calendar

From FDA's October 5 psychedelics docket to the DEA telehealth expiration and Medicare's 2027 in-person rule, six dates every ketamine clinic should plan around.

Read More

ARPA-H Is Now Funding Ibogaine Trials for Opioid Use Disorder

ARPA-H's ASCENT-IBO program funds Phase 1 and 2 ibogaine trials for opioid use disorder, with patient safety up front. Solution summaries are due October 15.

Read More

Definium’s LSD Tablet Clears a Third Phase 3, With a Design Aimed at the Blinding Problem

Definium's DT120 met its primary endpoint in the Panorama trial. A low-dose arm was added to address functional unblinding, and a dose-response pattern emerged.

Read More

The First Psilocybin Clinics Will Probably Be Spravato Clinics

Virginia passed a trigger law for FDA-approved psilocybin, and both Compass Pathways and Journey Clinical plan to launch at existing Spravato sites.

Read More

FDA’s Psychedelics Hearing Was Really a Fight Over the Label

FDA heard four hours of testimony on psychedelic approval and asked no questions. The real contest was over label language, which decides who can deliver these drugs.

Read More

Pharma Is Now Bidding on the Keywords Your Clinic Buys

Johnson & Johnson, Mindbloom and BetterU are all bidding on generic psychedelic search terms. Here is what that does to a local clinic's acquisition cost.

Read More

Psilocybin Protected Nerves From Chemo in Mice. A Non-Hallucinogenic Version Worked Too

A Science paper found psilocybin prevented chemotherapy nerve damage in mice across six treatment cycles. A non-hallucinogenic compound did the same.

Read More